Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]

Takamitsu Ohnishi; Shinichi Watanabe; Tetsuya Matsumoto; Hiroshi Yotsuyanagi; Junko Sato; Intestu Kobayashi; Shin Iinuma; Takashi Nagayama; Shuichiro Shibuya; Natsuki Ogawa; Ken Iozumi; Yasuyuki Nakajima; Yukiko Kurikawa; Motoko Kobayashi; Koma Matsuo; Hideyuki Ishikawa; Tadamichi Shimizu; Kiyohiro Tsutsui; Tatsuyoshi Kawamura; Ryuhei Okuyama; Mariko Seishima; Yoichi Akita; Chikatoshi Kasugai; Katsuaki Yano; Yasuhiko Tamada; Kimihiko Mizutani; Kenji Kabashima; Nanako Yamada; Masami Ikeda

doi:10.1016/j.jiac.2023.03.014

Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]

Takamitsu Ohnishi^*, Shinichi Watanabe, Tetsuya Matsumoto, Hiroshi Yotsuyanagi, Junko Sato, Intestu Kobayashi, Shin Iinuma, Takashi Nagayama, Shuichiro Shibuya, Natsuki Ogawa, Ken Iozumi, Yasuyuki Nakajima, Yukiko Kurikawa, Motoko Kobayashi, Koma Matsuo, Hideyuki Ishikawa, Tadamichi Shimizu, Kiyohiro Tsutsui, Tatsuyoshi Kawamura, Ryuhei OkuyamaMariko Seishima, Yoichi Akita, Chikatoshi Kasugai, Katsuaki Yano, Yasuhiko Tamada, Kimihiko Mizutani, Kenji Kabashima, Nanako Yamada, Masami Ikeda

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Comment/debate

Abstract

The authors would like to correct the funding. Funding This study was supported by grants from the following pharmaceutical companies (in alphabetical order): Astellas Pharma Inc., Choseido Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Daiichi-Sankyo Espha Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., GlaxoSmithKline. K.K., Kobayashi Kako Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Nipro Corporation., Ohara Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sawai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takata Pharmaceutical Co., Ltd., Teva Takeda Pharma Ltd., Towa Pharmaceutical Co., Ltd., and Yoshindo Inc.

Original language	English
Pages (from-to)	634-635
Number of pages	2
Journal	Journal of Infection and Chemotherapy
Volume	29
Issue number	6
DOIs	https://doi.org/10.1016/j.jiac.2023.03.014
State	Published - 2023/06

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jiac.2023.03.014

Fingerprint

Dive into the research topics of 'Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]'. Together they form a unique fingerprint.

Cite this

Ohnishi, T., Watanabe, S., Matsumoto, T., Yotsuyanagi, H., Sato, J., Kobayashi, I., Iinuma, S., Nagayama, T., Shibuya, S., Ogawa, N., Iozumi, K., Nakajima, Y., Kurikawa, Y., Kobayashi, M., Matsuo, K., Ishikawa, H., Shimizu, T., Tsutsui, K., Kawamura, T., ... Ikeda, M. (2023). Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]. Journal of Infection and Chemotherapy, 29(6), 634-635. https://doi.org/10.1016/j.jiac.2023.03.014

Ohnishi, Takamitsu ; Watanabe, Shinichi ; Matsumoto, Tetsuya et al. / Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]. In: Journal of Infection and Chemotherapy. 2023 ; Vol. 29, No. 6. pp. 634-635.

@article{0d1502643dd646a7824bfad8c1bd8e90,

title = "Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]",

abstract = "The authors would like to correct the funding. Funding This study was supported by grants from the following pharmaceutical companies (in alphabetical order): Astellas Pharma Inc., Choseido Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Daiichi-Sankyo Espha Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., GlaxoSmithKline. K.K., Kobayashi Kako Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Nipro Corporation., Ohara Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sawai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takata Pharmaceutical Co., Ltd., Teva Takeda Pharma Ltd., Towa Pharmaceutical Co., Ltd., and Yoshindo Inc.",

author = "Takamitsu Ohnishi and Shinichi Watanabe and Tetsuya Matsumoto and Hiroshi Yotsuyanagi and Junko Sato and Intestu Kobayashi and Shin Iinuma and Takashi Nagayama and Shuichiro Shibuya and Natsuki Ogawa and Ken Iozumi and Yasuyuki Nakajima and Yukiko Kurikawa and Motoko Kobayashi and Koma Matsuo and Hideyuki Ishikawa and Tadamichi Shimizu and Kiyohiro Tsutsui and Tatsuyoshi Kawamura and Ryuhei Okuyama and Mariko Seishima and Yoichi Akita and Chikatoshi Kasugai and Katsuaki Yano and Yasuhiko Tamada and Kimihiko Mizutani and Kenji Kabashima and Nanako Yamada and Masami Ikeda",

note = "Publisher Copyright: {\textcopyright} 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control",

year = "2023",

month = jun,

doi = "10.1016/j.jiac.2023.03.014",

language = "英語",

volume = "29",

pages = "634--635",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier B.V.",

number = "6",

}

Ohnishi, T, Watanabe, S, Matsumoto, T, Yotsuyanagi, H, Sato, J, Kobayashi, I, Iinuma, S, Nagayama, T, Shibuya, S, Ogawa, N, Iozumi, K, Nakajima, Y, Kurikawa, Y, Kobayashi, M, Matsuo, K, Ishikawa, H, Shimizu, T, Tsutsui, K, Kawamura, T, Okuyama, R, Seishima, M, Akita, Y, Kasugai, C, Yano, K, Tamada, Y, Mizutani, K, Kabashima, K, Yamada, N & Ikeda, M 2023, 'Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]', Journal of Infection and Chemotherapy, vol. 29, no. 6, pp. 634-635. https://doi.org/10.1016/j.jiac.2023.03.014

Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]. / Ohnishi, Takamitsu; Watanabe, Shinichi; Matsumoto, Tetsuya et al.
In: Journal of Infection and Chemotherapy, Vol. 29, No. 6, 06.2023, p. 634-635.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]

AU - Ohnishi, Takamitsu

AU - Watanabe, Shinichi

AU - Matsumoto, Tetsuya

AU - Yotsuyanagi, Hiroshi

AU - Sato, Junko

AU - Kobayashi, Intestu

AU - Iinuma, Shin

AU - Nagayama, Takashi

AU - Shibuya, Shuichiro

AU - Ogawa, Natsuki

AU - Iozumi, Ken

AU - Nakajima, Yasuyuki

AU - Kurikawa, Yukiko

AU - Kobayashi, Motoko

AU - Matsuo, Koma

AU - Ishikawa, Hideyuki

AU - Shimizu, Tadamichi

AU - Tsutsui, Kiyohiro

AU - Kawamura, Tatsuyoshi

AU - Okuyama, Ryuhei

AU - Seishima, Mariko

AU - Akita, Yoichi

AU - Kasugai, Chikatoshi

AU - Yano, Katsuaki

AU - Tamada, Yasuhiko

AU - Mizutani, Kimihiko

AU - Kabashima, Kenji

AU - Yamada, Nanako

AU - Ikeda, Masami

PY - 2023/6

Y1 - 2023/6

N2 - The authors would like to correct the funding. Funding This study was supported by grants from the following pharmaceutical companies (in alphabetical order): Astellas Pharma Inc., Choseido Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Daiichi-Sankyo Espha Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., GlaxoSmithKline. K.K., Kobayashi Kako Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Nipro Corporation., Ohara Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sawai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takata Pharmaceutical Co., Ltd., Teva Takeda Pharma Ltd., Towa Pharmaceutical Co., Ltd., and Yoshindo Inc.

AB - The authors would like to correct the funding. Funding This study was supported by grants from the following pharmaceutical companies (in alphabetical order): Astellas Pharma Inc., Choseido Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Daiichi-Sankyo Espha Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., GlaxoSmithKline. K.K., Kobayashi Kako Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Nipro Corporation., Ohara Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sawai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takata Pharmaceutical Co., Ltd., Teva Takeda Pharma Ltd., Towa Pharmaceutical Co., Ltd., and Yoshindo Inc.

UR - http://www.scopus.com/inward/record.url?scp=85151868644&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2023.03.014

DO - 10.1016/j.jiac.2023.03.014

M3 - コメント/討論

C2 - 37005215

AN - SCOPUS:85151868644

SN - 1341-321X

VL - 29

SP - 634

EP - 635

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

IS - 6

ER -

Ohnishi T, Watanabe S, Matsumoto T, Yotsuyanagi H, Sato J, Kobayashi I et al. Corrigendum to “The second nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan” [J. Infect. Chemother. 29 (2023) 143–149, (S1341321X22002884), (10.1016/j.jiac.2022.10.005)]. Journal of Infection and Chemotherapy. 2023 Jun;29(6):634-635. doi: 10.1016/j.jiac.2023.03.014